Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Flat | Up | Up |
| See historical APLS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Sep 20 | Crossed Above 20 DMA | Bullish | 0.00% |
| Sep 20 | Crossed Above 50 DMA | Bullish | 0.00% |
| Sep 20 | MACD Bullish Centerline Cross | Bullish | 0.00% |
| Sep 20 | MACD Bullish Signal Line Cross | Bullish | 0.00% |
| Sep 20 | Pocket Pivot | Bullish Swing Setup | 0.00% |
| Sep 20 | Multiple of Ten Bearish | Other | 0.00% |
| Sep 19 | 50 DMA Resistance | Bearish | 10.64% |
| Sep 19 | MACD Bearish Centerline Cross | Bearish | 10.64% |
| Sep 19 | Spinning Top | Other | 10.64% |
| Sep 19 | NR7 | Range Contraction | 10.64% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-10-30
- Sector: Healthcare
- Industry: Biopharmaceuticals
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more APLS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 32.0 |
| 52 Week Low | 12.45 |
| Average Volume | 240,776 |
| 200-Day Moving Average | 20.0203 |
| 50-Day Moving Average | 18.2 |
| 20-Day Moving Average | 18.601 |
| 10-Day Moving Average | 18.393 |
| Average True Range | 1.1812 |
| ADX | 17.7 |
| +DI | 25.5062 |
| -DI | 19.4597 |
| Chandelier Exit (Long, 3 ATRs ) | 16.6164 |
| Chandelier Exit (Short, 3 ATRs ) | 20.2936 |
| Upper Bollinger Band | 20.0729 |
| Lower Bollinger Band | 17.1291 |
| Percent B (%b) | 0.97 |
| BandWidth | 15.826031 |
| MACD Line | 0.097 |
| MACD Signal Line | 0.0174 |
| MACD Histogram | 0.0796 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 22.63 | ||||
| Resistance 3 (R3) | 22.35 | 21.18 | 22.18 | ||
| Resistance 2 (R2) | 21.18 | 20.51 | 21.32 | 22.03 | |
| Resistance 1 (R1) | 20.58 | 20.09 | 20.88 | 20.86 | 21.89 |
| Pivot Point | 19.41 | 19.41 | 19.57 | 19.55 | 19.41 |
| Support 1 (S1) | 18.81 | 18.74 | 19.11 | 19.09 | 18.05 |
| Support 2 (S2) | 17.64 | 18.32 | 17.78 | 17.91 | |
| Support 3 (S3) | 17.04 | 17.64 | 17.76 | ||
| Support 4 (S4) | 17.32 |
